Compare PXED & GERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PXED | GERN |
|---|---|---|
| Founded | 1976 | 1990 |
| Country | United States | United States |
| Employees | 3400 | 229 |
| Industry | Other Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.0B | 1.1B |
| IPO Year | N/A | N/A |
| Metric | PXED | GERN |
|---|---|---|
| Price | $28.93 | $1.31 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 7 | 3 |
| Target Price | ★ $44.29 | $2.17 |
| AVG Volume (30 Days) | 81.9K | ★ 15.7M |
| Earning Date | 04-07-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.07% | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $3.85 | $26.91 |
| Revenue Next Year | $4.49 | $43.75 |
| P/E Ratio | $11.20 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $23.52 | $1.04 |
| 52 Week High | $38.19 | $2.01 |
| Indicator | PXED | GERN |
|---|---|---|
| Relative Strength Index (RSI) | 50.20 | 32.86 |
| Support Level | $28.60 | $1.24 |
| Resistance Level | $30.68 | $1.49 |
| Average True Range (ATR) | 1.38 | 0.09 |
| MACD | 0.08 | -0.02 |
| Stochastic Oscillator | 52.89 | 0.00 |
Phoenix Education Partners Inc. is a mission-driven organization operating at the forefront of the rapidly evolving post-secondary education market. it is an online education provider and a pioneer in its field. The company benefits from the dynamic interplay between technological innovation, education, employment, and economic trends. It is focused on delivering personalized, career-relevant, and affordable education to its students through its flexible learning model, skills-aligned curriculum, and accessible tuition costs.
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.